Quinidine extended release - Beijing CoSci Med Tech

Drug Profile

Quinidine extended release - Beijing CoSci Med Tech

Latest Information Update: 03 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Beijing CoSci Med-Tech
  • Class Antiarrhythmics; Antimalarials; Cinchona alkaloids; Class Ia antiarrhythmics; Quinolines; Quinuclidines; Small molecules
  • Mechanism of Action Cytochrome P 450 enzyme system inhibitors; KATP channel inhibitors; Muscarinic receptor antagonists; Voltage-gated sodium channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase Unknown Atrial fibrillation; Atrial flutter; Ventricular arrhythmias

Most Recent Events

  • 03 Aug 2016 Chemical structure information added
  • 22 Jul 2016 Investigation in Atrial fibrillation in China (PO)
  • 22 Jul 2016 Investigation in Atrial flutter in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top